Catherine M. Green

Add links
Source: Wikipedia, the free encyclopedia.

Catherine Green
Imperial Cancer Research Fund (PhD)
Known forBiochemistry
Genome sequencing
Scientific career
InstitutionsUniversity of Sussex
Curie Institute
University of Oxford
ThesisThe Rad24 checkpoint protein of Saccharomyces cerevisiae : a complex problem.
Doctoral advisorNoel F. Lowndes[1]

Catherine Mary Green

OBE is an English biologist who is an Associate Professor in Chromosome Dynamics at the Wellcome Centre for Human Genetics at the University of Oxford. Her research considers chromosome stability during the replication of DNA. During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine
.

Early life and education

Green grew up in

Marie Curie Fellow.[2] Upon returning to the United Kingdom Green was appointed to the University of Sussex, where she studied DNA damage due to sunlight exposure.[2]

Research and career

Green was made a Cancer Research UK Research Fellow in the Department of Zoology at the University of Cambridge in 2008.[6] She held a Kaye Research Fellowship at Christ's College, Cambridge.[2] Her research considered the mechanisms of genome replication at the genetic and epigenetic levels.[6] During this replication process the mutations that are responsible for cancer can occur, or be fixed. Understanding the process that underpins this replication, and how cells control this replication, allows Green to better understand the development of cancer.[6][7]

In 2012 Green moved to the University of Oxford, where she joined the Wellcome Centre for Human Genetics. Here Green expanded her work in genomics to encompass the genetic and epigenetic stability of DNA.[8] Green was made Monsanto Senior Research Fellow at Exeter College, Oxford in 2017.[9] She leads the core facility in Chromosome Dynamics at the Wellcome Centre.[10]

During the

adenovirus vector (ChAdOx) that generated a strong immune response to SARS-CoV-2.[12] They used the SARS-CoV-2 genome that had beens sequenced by researchers in Wuhan. The adenovirus cannot replicate, so does not cause further infection, and instead acts as a vector to transfer the SARS-CoV-2 spike protein.[9] The spike protein, an external protein that enables the virus to enter cells, is responsible for the immune system response. In early April the team were awarded £22 million of funding from the Government of the United Kingdom to run human trials.[12] The vaccine underwent clinical trials in Oxford in April 2020, which were successful.[13] As of January 2022 more than 2.5 billion doses of the vaccine have been released to more than 170 countries worldwide.[14] In 2021 Green and Sarah Gilbert published Vaxxers: the inside story of the Oxford AstraZeneca vaccine and the race against the virus.[15][16]

Selected publications

Green has an h-index of 39 according to Google Scholar.[17] Her publications include:

  • Bienko, Marzena; Green, Catherine M.; Crosetto, Nicola; Rudolf, Fabian; Zapart, Grzegorz; Coull, Barry; Kannouche, Patricia; Wider, Gerhard; Peter, Matthias; Lehmann, Alan R.; Hofmann, Kay (16 December 2005). "Ubiquitin-Binding Domains in Y-Family Polymerases Regulate Translesion Synthesis". Science. 310 (5755): 1821–1824.
    S2CID 10666348.[18]
  • Lehmann, Alan R.; Niimi, Atsuko; Ogi, Tomoo; Brown, Stephanie; Sabbioneda, Simone; Wing, Jonathan F.; Kannouche, Patricia L.; Green, Catherine M. (1 July 2007). "Translesion synthesis: Y-family polymerases and the polymerase switch". DNA Repair. Replication Fork Repair Processes. 6 (7): 891–899.
    PMID 17363342.[19]
  • Gilbert, Christopher S; Green, Catherine M; Lowndes, Noel F (1 July 2001). "Budding Yeast Rad9 Is an ATP-Dependent Rad53 Activating Machine". Molecular Cell. 8 (1): 129–136.
    PMID 11511366.[20]
  • Gilbert, Sarah; Green, Catherine (2021). Vaxxers: the inside story of the Oxford AstraZeneca vaccine and the race against the virus. London: Hodder & Stoughton.
    ISBN 9781529369854
    .

References

  1. ^ "Cell Division Cycle Laboratory". Imperial Cancer Research Fund. 2000. Archived from the original on 25 October 2000.
  2. ^ a b c d e "Christ's College Magazine 2008". Issuu. Retrieved 24 April 2020.
  3. ^ "Weekly Bulletin: Mayfield Grammar School" (PDF). Mayfield Grammar School. Retrieved 20 July 2021.
  4. ^ "Churchill alumni listed in Queen's Birthday Honours". Churchill College, Cambridge. 11 June 2016. Retrieved 19 July 2021.
  5. PMID 9755168
    .
  6. ^ a b c "Dr Catherine Green PhD | Christs College Cambridge". www.christs.cam.ac.uk. Retrieved 24 April 2020.
  7. ^ Oxford, N. D. M. (21 November 2014), Catherine Green: DNA replication and cancer, retrieved 24 April 2020
  8. ^ "Department of Zoology, University of Cambridge, United Kingdom". Epigenesys. Retrieved 24 April 2020.
  9. ^ a b c "Exeter Fellow Dr Catherine Green leads the production of a potential COVID-19 vaccine in Oxford". Exeter College. 6 April 2020. Retrieved 24 April 2020.
  10. ^ "Catherine Green — Wellcome Centre for Human Genetics". www.well.ox.ac.uk. Retrieved 24 April 2020.
  11. ^ "Hear from the Oxford COVID-19 vaccine team | Science Media Centre". Retrieved 24 April 2020.
  12. ^ a b c Hoare, Callum (2 April 2020). "Oxford University scientist tips miracle COVID-19 'neutraliser' for NHS frontline staff". Express.co.uk. Retrieved 24 April 2020.
  13. ^ "Coronavirus vaccine: Professor behind trial tells James O'Brien what happens next". LBC. Retrieved 24 April 2020.
  14. ^ "One year anniversary of UK deploying Oxford-AstraZeneca vaccine". gov.uk. Retrieved 4 January 2022.
  15. ^ Honigsbaum, Mark (11 July 2021). "Vaxxers by Sarah Gilbert and Catherine Green; Until Proven Safe by Geoff Manaugh and Nicola Twilley – reviews". The Guardian. Retrieved 12 June 2022.
  16. S2CID 236883504
    .
  17. ^ "Catherine Green". Google Scholar. Retrieved 19 July 2021.
  18. S2CID 10666348
    .
  19. PMID 17363342
    .
  20. PMID 11511366
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Catherine_M._Green&oldid=1217661311"